Targeting systemic and gut microbial metabolism in ER+ breast cancer

Hannah Heath, Ayca Nazli Mogol, Ashlie Santaliz Casiano, Qianying Zuo, Zeynep Madak-Erdogan

Research output: Contribution to journalReview articlepeer-review


Estrogen receptor-positive (ER+) breast tumors have a better overall prognosis than ER tumors; however, there is a sustained risk of recurrence. Mounting evidence indicates that genetic and epigenetic changes associated with resistance impact critical signaling pathways governing cell metabolism. This review delves into recent literature concerning the metabolic pathways regulated in ER+ breast tumors by the availability of nutrients and endocrine therapies and summarizes research on how changes in systemic and gut microbial metabolism can affect ER activity and responsiveness to endocrine therapy. As targeting of metabolic pathways using dietary or pharmacological approaches enters the clinic, we provide an overview of the supporting literature and suggest future directions.

Original languageEnglish (US)
Pages (from-to)321-330
Number of pages10
JournalTrends in Endocrinology and Metabolism
Issue number4
StatePublished - Apr 2024
Externally publishedYes

All Science Journal Classification (ASJC) codes

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology


  • breast cancer
  • diet
  • estrogen receptor
  • metabolism
  • microbiome
  • therapy resistance


Dive into the research topics of 'Targeting systemic and gut microbial metabolism in ER+ breast cancer'. Together they form a unique fingerprint.

Cite this